

7. The crystalline form according to claim 6, characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 5.4° , 8.5° , and 10.8° .
- 5 8. The crystalline form according to claim 6, characterised by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.2° , 5.4° , 8.0° , 8.5° , and 10.8° .
9. The crystalline form according to claim 6, characterised by the presence of peaks in the
10 X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.2° , 5.4° , 8.0° , 8.5° , 10.8° , 12.7° , 14.4° , 17.7° , 20.4° , and 21.3° .
10. The crystalline form according to claim 6, which essentially shows the X-ray powder diffraction pattern as depicted in Fig. 1.
- 15 11. The crystalline form according to any one of claims 6 to 10, which has a melting point of about 79°C as determined by differential scanning calorimetry.
12. The crystalline form according to any one of claims 1 to 5, obtainable by the processes
20 of claim 6.
13. A pharmaceutical composition comprising the crystalline form according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier.
- 25 14. The crystalline form according to any one of claims 1 to 12, or a pharmaceutical composition according to claim 13, for use as a medicament.
15. Use of the crystalline form according to any one of claims 1 to 12, or a pharmaceutical composition according to claim 13, for the preparation of a medicament for the
30 prevention or treatment of a disease or disorder associated with an activated immune system.
16. Use of the crystalline form according to any one of claims 1 to 12, or a pharmaceutical composition according to claim 13, for the preparation of a medicament for the
35 prevention or treatment of a disease or disorder selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host disease; autoimmune syndromes including Sjögren's syndrome, spondylarthropathy / ankylosing

- spondylitis, juvenile arthritis, subacute cutaneous lupus, discoid lupus erythematosus, lupus nephritis, systemic sclerosis, diffuse cutaneous systemic sclerosis, vasculitis (e.g. M. Wegener), giant cell arteritis, Behcet disease, non-infectious uveitis, Goodpasture syndrome, Grave's disease, Guillain Barré syndrome, primary biliary cirrhosis, primary
- 5 sclerosing cholangitis, autoimmune hepatitis, polymyositis, dermatomyositis, microscopic colitis, celiac disease, sarcoidosis, vitiligo, alopecia areata, chronic inflammatory demyelinating polyneuropathy (CIDP), Rasmussen's encephalitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative
- 10 colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, uveo-retinitis, and systemic lupus erythematosus; atopic diseases such as rhinitis, conjunctivitis, and atopic dermatitis; asthma; type I diabetes; and post-infectious autoimmune diseases including rheumatic fever.
17. Use of the crystalline form according to any one of claims 1 to 12, or a pharmaceutical
- 15 composition according to claim 13, for the preparation of a medicament for the treatment of systemic lupus erythematosus.